TNDM Stock Analysis: Tandem Diabetes Care | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.053m USD | 12M Return: -4.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.7M
Qual. Beats: 1
Rev. Trend: 82.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a U.S.-based medical device company that designs, develops, and commercializes technology solutions for people living with diabetes, operating domestically and internationally. Its flagship offerings include the t:slim X2 insulin delivery system and the Tandem Mobi automated insulin pump, supported by a recurring revenue stream from single-use products such as insulin cartridges and infusion sets. The company also provides complementary digital tools, including the Tandem Device Updater, the Tandem Source data management platform, and the Sugarmate mobile app, and maintains a research collaboration with the University of Virginia Center for Diabetes Technology on closed-loop insulin delivery systems.
Founded in 2006 and headquartered in San Diego, California, Tandem Diabetes Care was originally known as Phluid Inc. before adopting its current name in January 2008. The company operates within the Health Care Equipment sub-industry, where diabetes management devices represent a growing segment driven by rising diabetes prevalence and increasing adoption of automated insulin delivery technologies.
- Tandem Mobi pump shipments accelerate US new pump revenue growth
- Insulet OmniPod 5 competition pressures market share and pricing
- Recurring consumables revenue scales with growing installed base
- International expansion and Type 2 diabetes label broaden addressable market
| Net Income: -94.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 7.04 > 1.0 |
| NWC/Revenue: 62.20% < 20% (prev 34.04%; Δ 28.16% < -1%) |
| CFO/TA 0.02 > 3% & CFO 19.6m > Net Income -94.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.4m) vs 12m ago 3.00% < -2% |
| Gross Margin: 54.93% > 18% (prev 46.57%; Δ 8.36% > 0.5%) |
| Asset Turnover: 99.01% > 50% (prev 119.5%; Δ -20.52% > 0%) |
| Interest Coverage Ratio: -10.81 > 6 (EBIT TTM -89.8m / Interest Expense TTM 8.30m) |
| A: 0.55 (Total Current Assets 887.1m - Total Current Liabilities 248.0m) / Total Assets 1.15b |
| B: -1.10 (Retained Earnings -1.27b / Total Assets 1.15b) |
| C: -0.09 (EBIT TTM -89.8m / Avg Total Assets 1.04b) |
| D: 0.13 (Book Value of Equity 132.4m / Total Liabilities 1.02b) |
| Altman-Z'' = -0.41 = B |
| DSRI: 1.19 (Receivables 140.7m/126.6m, Revenue 1.03b/1.10b) |
| GMI: 0.85 (GM 46.57% / 54.93%) |
| AQI: 0.89 (AQ_t 0.08 / AQ_t-1 0.09) |
| SGI: 0.93 (Revenue 1.03b / 1.10b) |
| TATA: -0.10 (NI -94.5m - CFO 19.6m) / TA 1.15b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 15.41 with a total of 1,320,894 shares traded. Over the past week, the price has changed by +0.59%, over one month by -5.05%, over three months by -19.66% and over the past year by -4.70%.
Current recommended Stop Loss: 13.00 (which is 15.6% or 2.4 ATR below the current price).
Tandem Diabetes Care has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold TNDM.
- StrongBuy: 6
- Buy: 4
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 28.9 | 87.4% |
P/E Forward = 1111.1111
P/S = 1.0251
P/B = 7.8465
Revenue TTM = 1.03b USD
EBIT TTM = -89.8m USD
EBITDA TTM = -71.9m USD
Long Term Debt = 601.8m USD (from longTermDebt, last quarter)
Short Term Debt = 20.1m USD (from shortTermDebt, last quarter)
Debt = 867.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 133.0m
Net Debt = 297.4m USD (calculated: Debt 867.7m - CCE 570.3m)
Enterprise Value = 1.35b USD (1.05b + Debt 867.7m - CCE 570.3m)
Interest Coverage Ratio = -10.81 (Ebit TTM -89.8m / Interest Expense TTM 8.30m)
EV/FCF = -74.49x (Enterprise Value 1.35b / FCF TTM -18.1m)
FCF Yield = -1.34% (FCF TTM -18.1m / Enterprise Value 1.35b)
FCF Margin = -1.76% (FCF TTM -18.1m / Revenue TTM 1.03b)
Net Margin = -9.20% (Net Income TTM -94.5m / Revenue TTM 1.03b)
Gross Margin = 54.93% ((Revenue TTM 1.03b - Cost of Revenue TTM 463.1m) / Revenue TTM)
Gross Margin QoQ = 55.33% (prev 57.67%)
Tobins Q-Ratio = 1.17 (Enterprise Value 1.35b / Total Assets 1.15b)
Interest Expense / Debt = 0.96% (Interest Expense 8.30m / Debt 867.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -70.9m (EBIT -89.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.88 (Total Current Assets 887.1m / Total Current Liabilities 307.8m)
Debt / Equity = 6.55 (Debt 867.7m / totalStockholderEquity, last quarter 132.4m)
Debt / EBITDA = -4.14 (negative EBITDA) (Net Debt 297.4m / EBITDA -71.9m)
Debt / FCF = -16.40 (negative FCF - burning cash) (Net Debt 297.4m / FCF TTM -18.1m)
Total Stockholder Equity = 138.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.11% (Net Income -94.5m / Total Assets 1.15b)
RoE = -68.29% (Net Income TTM -94.5m / Total Stockholder Equity 138.5m)
RoCE = -12.13% (EBIT -89.8m / Capital Employed (Equity 138.5m + L.T.Debt 601.8m))
RoIC = -8.11% (negative operating profit) (NOPAT -70.9m / Invested Capital 874.2m)
WACC = 5.80% (E(1.05b)/V(1.92b) * Re(9.96%) + D(867.7m)/V(1.92b) * Rd(0.96%) * (1-Tc(0.21)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.03%
[DCF] Fair Price = unknown (Cash Flow -18.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.34 | # QB: 1
Revenue Correlation: 82.80 | Revenue CAGR: 15.62% | SUE: 0.15 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.33 | Chg30d=+2.04% | Revisions=+40% | Analysts=18
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=-5.61% | Revisions=-40% | Analysts=18
EPS current Year (2026-12-31): EPS=-0.71 | Chg30d=-1.00% | Revisions=-40% | GrowthEPS=+72.6% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=0.08 | Chg30d=+47.63% | Revisions=+0% | GrowthEPS=+111.0% | GrowthRev=+12.2%
[Analyst] Revisions Ratio: -18% (up=3, down=5)